On the one hand, the efficacy of Aduhelm is unproven; patients face serious risks; and the drug's FDA approval was extremely controversial, so Medicare officials faced a real dilemma. On the other hand, what would have been the implications if clinical trials had clearly demonstrated that the drug could slow cognitive decline and Biogen had kept the price at $56,000 per year?
In a social media landscape shaped by hashtags, algorithms, and viral posts, nurse leaders must decide: Will they let the narrative spiral, or can they adapt and join the conversation?
...
